VeinSound

Executive Summary

VeinSound is a French medical device company pioneering a non-invasive, AI-powered treatment for varicose veins. Its investigational platform uses High-Intensity Focused Ultrasound (HIFU) with a non-thermal cavitation mechanism to precisely obliterate targeted veins, offering a painless, scar-free alternative to conventional surgery or injection therapies. Designed for in-office use, the device aims to reduce patient downtime and healthcare costs. Founded in 2015, VeinSound is positioned in the rapidly growing varicose vein treatment market, driven by rising demand for minimally invasive procedures. The company's technology leverages real-time AI guidance for enhanced safety and efficacy, differentiating it from existing thermal-based HIFU systems. The company has likely completed preclinical or early feasibility studies, with plans to initiate pivotal clinical trials. Varicose vein therapy represents a multi-billion-dollar global market, and VeinSound's approach could capture significant share if clinical endpoints are met. As a private entity, funding and strategic partnerships are critical for advancement. The near-term focus includes securing regulatory approvals (CE mark and FDA clearance) and building clinical evidence. While specific financial and operational details are limited, the company's strong intellectual property and experienced team position it as a promising player in interventional phlebology.

Upcoming Catalysts (preview)

• Q3 2026Completion of First-in-Human Clinical Trial70% success
• TBDCE Mark Submission for European Approval60% success
• H2 2026Series B Funding Round or Strategic Partnership50% success